** Shares of drug developer Gritstone bio fall 29.4% to 14 cents premarket
** Company files for Chapter 11 bankruptcy
** GRTS lists both estimated assets and liabilities at $100 million to $500 million - court filing
** "During its financial restructuring process, Gritstone intends to operate in the ordinary course and remains committed to advancing its clinical programs" - company
** Up to last close, stock down 90.3% YTD
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments